Hypochondroplasia
11
5
6
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (11)
Prospective Clinical Assessment Study in Children With Hypochondroplasia
An Interventional Study of Infigratinib in Children With Hypochondroplasia
Open-Label, Long-Term, Extension Study of Infigratinib in Children With Hypochondroplasia
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal Dysplasia
Interventional Study of Vosoritide for the Treatment of Children With Hypochondroplasia
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
A Multicenter Multinational Observational Study of Children With Hypochondroplasia
Registry for Patients With Achondroplasia / Hypochondroplasia (OMPR-Ach/Hy)
Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children
C-Type Natriuretic Peptide and Achondroplasia